Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof
US11858933B2 · kind B2 · utility
0Cited by
2References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2023 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Jun 30, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.